Life sciences

DGAP-News: MorphoSys and Incyte to Host Investor Event to Discuss the Unmet Need and Global Opportunities for Tafasitamab in Non-Hodgkin Lymphomas

Thursday, September 17, 2020 - 10:05pm

Dr. Gilles Salles will join MorphoSys and Incyte leadership as an expert speaker.

Key Points: 
  • Dr. Gilles Salles will join MorphoSys and Incyte leadership as an expert speaker.
  • The conference call and webcast will be held on Tuesday, September 29, 2020 from 9:00 - 11:00 a.m. EDT / 3:00 - 5:00 p.m. CEST.
  • In January 2020, MorphoSys and Incyte entered into a collaboration and licensing agreement to further develop and commercialize tafasitamab globally.
  • Serious infections, including infections that can cause death, have happened in people during treatments with MONJUVI and after the last dose.

Geron Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Thursday, September 17, 2020 - 9:30pm

Geron Corporation (Nasdaq: GERN) today reported that it has granted a non-statutory stock option to purchase an aggregate of 80,000 shares of Geron common stock as an inducement to a newly-hired employee in connection with commencement of employment with the Company.

Key Points: 
  • Geron Corporation (Nasdaq: GERN) today reported that it has granted a non-statutory stock option to purchase an aggregate of 80,000 shares of Geron common stock as an inducement to a newly-hired employee in connection with commencement of employment with the Company.
  • The stock option was granted on September 16, 2020 at an exercise price of $1.81 per share, which is equal to the closing price of Geron common stock on the date of grant.
  • The option was granted as a material inducement to employment in accordance with Nasdaq Listing Rule 5635(c)(4) and is subject to the terms and conditions of a stock option agreement covering the grant and Gerons 2018 Inducement Award Plan, which was adopted December 14, 2018 and provides for the granting of stock options to new employees.
  • Geron is a late-stage clinical biopharmaceutical company focused on the development and potential commercialization of a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies.

QIAGEN fully acquires NeuMoDx Molecular, Inc., rounding out portfolio of PCR-based diagnostic automation systems

Thursday, September 17, 2020 - 9:05pm

The move rounds out QIAGENs portfolio of automated molecular testing solutions based on the proven PCR technology.

Key Points: 
  • The move rounds out QIAGENs portfolio of automated molecular testing solutions based on the proven PCR technology.
  • The transaction was completed after QIAGEN received U.S. regulatory clearance for the full acquisition.
  • In 2018, QIAGEN had purchased a 19.9% stake in NeuMoDx along with the right to acquire the remaining NeuMoDx stake at a price of $234 million.
  • The full integration of the NeuMoDx systems will allow QIAGEN to address laboratory needs in almost any setting for molecular diagnostics.

Bristol Myers Squibb to Announce Results for Third Quarter 2020 on November 5, 2020

Thursday, September 17, 2020 - 9:16pm

Bristol Myers Squibb (NYSE:BMY) will announce results for the third quarter of 2020 on Thursday, November 5, 2020.

Key Points: 
  • Bristol Myers Squibb (NYSE:BMY) will announce results for the third quarter of 2020 on Thursday, November 5, 2020.
  • ET on November 5, 2020, company executives will review financial results and will address inquiries from investors and analysts.
  • Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.
  • For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn , Twitter , YouTube , Facebook , and Instagram .

Magnolia Medical Appoints Former Becton Dickinson Senior Executives to Its Medical & Scientific Advisory Board

Thursday, September 17, 2020 - 6:15pm

The MSAB board will continue to focus on Magnolia's new advanced products and integrated diagnostic technologies to reduce blood culture contamination and improve sepsis testing accuracy.

Key Points: 
  • The MSAB board will continue to focus on Magnolia's new advanced products and integrated diagnostic technologies to reduce blood culture contamination and improve sepsis testing accuracy.
  • The Diagnostic Systems business unit comprised several BD Market Segment Areas including Molecular Diagnostics, Women's Health and Cancer, Microbiology, and Point of Care Diagnostics.
  • I look forward to contributing to Magnolia's Medical & Scientific Advisory Board to guide development of innovative solutions for sepsis management."
  • Magnolia Medical invented and patented the Initial Specimen Diversion Technique (ISDT) and Device (ISDD) for blood culture collection and contamination prevention.

Venatorx Pharmaceuticals Names William Sargent Senior Vice President, Commercial Strategy

Thursday, September 17, 2020 - 3:00pm

Venatorx Pharmaceuticals today announced that Will Sargent has joined the Company as Senior Vice President, Commercial Strategy.

Key Points: 
  • Venatorx Pharmaceuticals today announced that Will Sargent has joined the Company as Senior Vice President, Commercial Strategy.
  • View the full release here: https://www.businesswire.com/news/home/20200917005087/en/
    William Sargent Jr. - Senior Vice President, Commercial Strategy at Venatorx Pharmaceuticals, Inc. (Photo: Business Wire)
    Will has a proven track record of success and extensive expertise across a wide array of therapeutic areas, most notably in antibiotics, said Christopher J. Burns, Ph.D. , President and CEO of Venatorx.
  • Prior to joining Venatorx, Mr. Sargent served as Vice President, Commercial Strategy at Nabriva where he led the launch and commercialization for Xenleta, a novel antibiotic approved for the treatment of community acquired bacterial pneumonia (CABP).
  • Before Auxilium, Mr. Sargent was a biotechnology equities analyst at Bank of America and held multiple commercial roles at Amgen and Immunex.

Celltrion receives Korean MFDS approval to initiate Phase II/III pivotal trial of an anti-COVID-19 monoclonal antibody treatment candidate, CT-P59

Thursday, September 17, 2020 - 2:33pm

Celltrion Group announced today that the Korean Ministry of Food and Drug Safety (MFDS) has approved the companys Investigational New Drug (IND) application for a Phase II/III pivotal clinical trial of CT-P59, an anti-COVID-19 monoclonal antibody treatment candidate.

Key Points: 
  • Celltrion Group announced today that the Korean Ministry of Food and Drug Safety (MFDS) has approved the companys Investigational New Drug (IND) application for a Phase II/III pivotal clinical trial of CT-P59, an anti-COVID-19 monoclonal antibody treatment candidate.
  • Celltrion is set to obtain the summary of the primary results for Phase II of the study by the end of the year.
  • The company expects to be able to apply for emergency use authorisation (EUA), conditional on the results of the pivotal trial.
  • The initiation of the global Phase II/III pivotal trial of CT-P59 is an important step forward, and together with the ongoing Phase I trial in patients with mild symptoms, Celltrion remains committed to investigating a potential anti-COVID-19 monoclonal antibody treatment, said Dr.

Dr. Reddy's Laboratories announces settlement of U.S. Revlimid® (lenalidomide) Capsules patent litigation with Celgene, a Bristol Myers Squibb Company

Thursday, September 17, 2020 - 1:03pm

Dr. Reddys Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as Dr. Reddys), today announced the settlement of their litigation with Celgene, a wholly owned subsidiary of Bristol Myers Squibb (NYSE: BMY), relating to patents for REVLIMID (lenalidomide) Capsules.

Key Points: 
  • Dr. Reddys Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as Dr. Reddys), today announced the settlement of their litigation with Celgene, a wholly owned subsidiary of Bristol Myers Squibb (NYSE: BMY), relating to patents for REVLIMID (lenalidomide) Capsules.
  • Dr. Reddys is also licensed to sell generic lenalidomide capsules in the U.S. without volume limitation beginning on January 31, 2026.
  • Revlimid is a trademark of Celgene, a wholly owned subsidiary of Bristol Myers Squibb.
  • About Dr. Reddys: Dr. Reddys Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives.

Octapharma Chooses Genedata Selector for NGS-Based Cell Line Development

Thursday, September 17, 2020 - 1:00pm

BASEL,Switzerland, Sept. 17, 2020 /PRNewswire-PRWeb/ -- Genedata, the leading provider of enterprise software solutions for biopharmaceutical R&D, today announced that Octapharma, one of the world's leading manufacturers of therapeutic human proteins, has chosen Genedata Selector as its central computational platform to streamline genomics-based cell line development and cell culture optimization workflows.

Key Points: 
  • BASEL,Switzerland, Sept. 17, 2020 /PRNewswire-PRWeb/ -- Genedata, the leading provider of enterprise software solutions for biopharmaceutical R&D, today announced that Octapharma, one of the world's leading manufacturers of therapeutic human proteins, has chosen Genedata Selector as its central computational platform to streamline genomics-based cell line development and cell culture optimization workflows.
  • Genedata Selector enables the efficient analysis of next-generation sequencing (NGS) data in the context of host cell line engineering and clone selection.
  • "For example, using Genedata Selector we are now able to quickly detect unfavorable properties of a production cell line and engineer preferred properties by editing its genetic background."
  • "We are excited to collaborate with Octapharma in supporting their innovative cell line development projects," said Othmar Pfannes, Ph.D., CEO of Genedata.

Olema Oncology Names Sean P. Bohen, M.D., Ph.D., President and Chief Executive Officer

Thursday, September 17, 2020 - 1:00pm

Dr. Bohen, a pharmaceutical and biotechnology industry executive with a track record of developing numerous oncology drugs, was most recently Executive Vice President of Global Medicines Development and Chief Medical Officer at AstraZeneca.

Key Points: 
  • Dr. Bohen, a pharmaceutical and biotechnology industry executive with a track record of developing numerous oncology drugs, was most recently Executive Vice President of Global Medicines Development and Chief Medical Officer at AstraZeneca.
  • Dr. Bohen succeeds Cyrus Harmon, Ph.D., who had served as President and Chief Executive Officer of Olema since the company was founded.
  • Adding Sean as President and Chief Executive Officer brings further skills and experience to take Olema through our next stages of growth and OP-1250 through clinical trials.
  • Dr. Bohen served as Executive Vice President of Global Medicines Development and Chief Medical Officer at AstraZeneca from 2015 to 2019.